UM
SUPN icon

UniSuper Management’s Supernus Pharmaceuticals SUPN Stock Holding History

UniSuper Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-15,072
Closed -$403K – 945
2024
Q2 		$403K Hold
15,072
– – ﹤0.01% 844
2024
Q1 		$514K Buy
+15,072
New +$449K ﹤0.01% 739

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UniSuper Management's SUPN Position: Q3 2024 in Review

UniSuper Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2024, closing a stake of 15,072 shares — an estimated $403K sold.

UniSuper Management first reported a position in SUPN in Q1 2024 and held it in 2 quarters. The position peaked at $514K in Q1 2024. 273 funds tracked by Wall St. Rank hold SUPN as of Q3 2024.

  • UniSuper Management reported no remaining Supernus Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • UniSuper Management sold 15,072 Supernus Pharmaceuticals shares in Q3 2024, an estimated $403K.
  • UniSuper Management first reported a position in Supernus Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • UniSuper Management's Supernus Pharmaceuticals position peaked at $514K in Q1 2024.
  • 273 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2024.

Based on UniSuper Management's 13F filing for Q3 2024, filed 14 Nov 2024.